Pharma BD Deal Intelligence
Genmab to acquire Seattle company ProfoundBio in $1.8B deal for next-gen ADC technologies.
FDA granted Breakthrough Therapy Designation to Rina-S for recurrent or progressive endometrial cancer after platinum + PD-(L)1, supported by the RAINFOL-01…
FDA granted BTD for recurrent or progressive endometrial cancer (Aug 2025). RAINFOL-02 (NCT06619236) in 2L+ PROC completed enrollment in March 2026. Rina-S…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Genmab acquired ProfoundBio for $1.8 billion in an all-cash transaction (announced April 3, 2024; closed May 21, 2024), gaining rinatabart sesutecan (Rina-S), an FRalpha-targeted Topo1-inhibitor ADC, plus ProfoundBio's ADC platform and earlier candidates. Since the acquisition the asset has materially de-risked: Rina-S advanced from Phase 1/2 at deal to a broad late-stage program, securing FDA Breakthrough Therapy Designation in recurrent/progressive endometrial cancer (August 2025) on top of its January 2024 Fast Track in FRalpha-expressing platinum-resistant ovarian cancer. The pivotal Phase 3 RAINFOL-02 trial in 2L+ platinum-resistant ovarian cancer completed enrollment in March 2026, and Genmab now names Rina-S among its core late-stage launch-readiness assets alongside EPKINLY and petosemtamab, with three active Phase 3 trials (2L+ PROC, 2L PSOC maintenance, 2L+ endometrial) plus a Phase 2 NSCLC study.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genmab A/S / ProfoundBio Inc. (this deal) | 2024 | $1.8B | 64 |
| Genmab A/S / Merus N.V. | 2025 | $8.0B | — |
| Genmab A/S / Bolt Biotherapeutics, Inc. | 2021 | $880M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2024 deals · Genmab A/S deals · Oncology deals